Literature DB >> 1510393

A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.

L J Piddock1, M C Hall, F Bellido, M Bains, R E Hancock.   

Abstract

An enoxacin-resistant Pseudomonas aeruginosa mutant (G49) isolated during patient therapy was characterized in detail. The G49 mutant was cross resistant to several classes of antibiotics including quinolones, beta-lactams, chloramphenicol, and tetracycline, but not imipenem or aminoglycosides. Compared with its paired pretherapy isolate G48, this mutant had several alterations in outer membrane proteins including a complete loss of the major porin protein OprF and a substantially altered lipopolysaccharide profile. Revertants were selected at a frequency of approximately 1% after enrichment for OprF+ cells on low-salt proteose peptone no. 2 medium. Ninety-seven of these OprF+ revertants were as susceptible to carbenicillin and norfloxacin as the pretherapy isolate. One of these revertants was characterized in more detail and shown to be indistinguishable in all properties from the pretherapy isolate. It is proposed that the multiple-antibiotic-resistance (Mar) phenotype of this mutant resulted from a single pleiotropic mutation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510393      PMCID: PMC188835          DOI: 10.1128/AAC.36.5.1057

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  A J Lesse; A A Campagnari; W E Bittner; M A Apicella
Journal:  J Immunol Methods       Date:  1990-01-24       Impact factor: 2.303

2.  Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacin.

Authors:  N J Legakis; L S Tzouvelekis; A Makris; H Kotsifaki
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency.

Authors:  S Chamberland; F Malouin; H R Rabin; T Schollaardt; T R Parr; L E Bryan
Journal:  J Antimicrob Chemother       Date:  1990-06       Impact factor: 5.790

4.  Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa.

Authors:  D M Benbrook; R V Miller
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

5.  Identification of porins in the outer membrane of Pseudomonas aeruginosa that form small diffusion pores.

Authors:  E Yoshihara; T Nakae
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

6.  Outer membrane of Pseudomonas aeruginosa: heat- 2-mercaptoethanol-modifiable proteins.

Authors:  R E Hancock; A M Carey
Journal:  J Bacteriol       Date:  1979-12       Impact factor: 3.490

7.  Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa.

Authors:  H Yoshida; M Nakamura; M Bogaki; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  Identification and characterization of porins in Pseudomonas aeruginosa.

Authors:  H Nikaido; K Nikaido; S Harayama
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

9.  Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes.

Authors:  M Rella; D Haas
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

10.  Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.

Authors:  N J Robillard; A L Scarpa
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

View more
  20 in total

1.  The amino terminus of Pseudomonas aeruginosa outer membrane protein OprF forms channels in lipid bilayer membranes: correlation with a three-dimensional model.

Authors:  F S Brinkman; M Bains; R E Hancock
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

2.  Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa.

Authors:  L Pumbwe; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 3.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Pharmacodynamic parameters of aminoglycosides and their effect on exoenzymes of Pseudomonas aeruginosa.

Authors:  A Hostacká
Journal:  Folia Microbiol (Praha)       Date:  1996       Impact factor: 2.099

Review 5.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

6.  Conservation of the multidrug resistance efflux gene oprM in Pseudomonas aeruginosa.

Authors:  N Bianco; S Neshat; K Poole
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 7.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Cell Envelope Changes in Solvent-Tolerant and Solvent-Sensitive Pseudomonas putida Strains following Exposure to o-Xylene.

Authors:  H C Pinkart; J W Wolfram; R Rogers; D C White
Journal:  Appl Environ Microbiol       Date:  1996-03       Impact factor: 4.792

9.  Differential impact of MexB mutations on substrate selectivity of the MexAB-OprM multidrug efflux pump of Pseudomonas aeruginosa.

Authors:  Jocelyn K Middlemiss; Keith Poole
Journal:  J Bacteriol       Date:  2004-03       Impact factor: 3.490

10.  Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon.

Authors:  K Poole; K Krebes; C McNally; S Neshat
Journal:  J Bacteriol       Date:  1993-11       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.